Dietary Fatty Acids and Their Potential for Controlling Metabolic Diseases Through Activation of FFA4-GPR120

Annual Review of Nutrition

Volumn 35, Issue 1, 2015, Pages 239-263

  Ulven, Trond ^a   Christiansen, Elisabeth ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

7 transmembrane receptors; Fatty acids; GPR120; GPR40

Indexed keywords

ACETYL COENZYME A; ACYL COENZYME A DESATURASE; ARACHIDONIC ACID; CHOLECYSTOKININ; CONJUGATED LINOLEIC ACID; CYCLOOXYGENASE 2; DOCOSAHEXAENOIC ACID; EPOXYICOSATRIENOIC ACID; ESSENTIAL FATTY ACID; FASIGLIFAM; FISH OIL; G PROTEIN COUPLED RECEPTOR 120; GHRELIN; GLUCAGON LIKE PEPTIDE 1; GSK 137647A; ICOSAPENTAENOIC ACID; LINOLEIC ACID; LINOLENIC ACID; MONOUNSATURATED FATTY ACID; OLEIC ACID; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; PALMITOLEIC ACID; SATURATED FATTY ACID; STEARIDONIC ACID; SULFONAMIDE; TRANS FATTY ACID; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; FAT INTAKE; FATTY ACID; G PROTEIN COUPLED RECEPTOR; HORMONE; O3FAR1 PROTEIN, HUMAN;

ADIPOSE TISSUE; ANTIINFLAMMATORY ACTIVITY; BODY WEIGHT; DRUG WITHDRAWAL; FAT INTAKE; GLUCAGON RELEASE; HORMONE RELEASE; HUMAN; INFLAMMATION; INSULIN RELEASE; INSULIN RESISTANCE; LIVER TOXICITY; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUTRITION; OBESITY; PERSONALIZED MEDICINE; PHYLOGENY; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; STOMACH BYPASS; ADMINISTRATION AND DOSAGE; DIABETES MELLITUS, TYPE 2; DIET; DRUG EFFECTS; EATING; LIVER; METABOLIC DISEASES; PHYSIOLOGY; SECRETION (PROCESS); SIGNAL TRANSDUCTION; TASTE BUD;

ADIPOSE TISSUE; ANTI-INFLAMMATORY AGENTS; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DIET; DIETARY FATS; EATING; FATTY ACIDS; FATTY ACIDS, NONESTERIFIED; HORMONES; HUMANS; LIVER; METABOLIC DISEASES; NUTRITIONAL PHYSIOLOGICAL PHENOMENA; OBESITY; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; TASTE BUDS;

EID: 84937576781     PISSN: 01999885     EISSN: 15454312     Source Type: Book Series    
DOI: 10.1146/annurev-nutr-071714-034410     Document Type: Review

References (143)

1. Adachi T, Yanaka H, Kanai H, Nozaki M, Takahara Y, et al. 2008. Administration of perilla oil coated with Calshell increases glucagon-like peptide secretion. Biol. Pharm. Bull. 31:1021-23
2. Arterburn LM, Hall EB, Oken H. 2006. Distribution, interconversion, and dose response of n-3 fatty acids in humans. Am. J. Clin. Nutr. 83:S1467-76
3. Astrup A. 2014. A changing view on saturated fatty acids and dairy: from enemy to friend. Am. J. Clin. Nutr. 100:1407-8
4. Axelsen LN, KeungW, PedersenHD, Meier E, Riber D, et al. 2012. Glucagon and a glucagon-GLP-1 dual-agonist increases cardiac performance with different metabolic effects in insulin-resistant hearts. Br. J. Pharmacol. 165:2736-48
5. Back M, Dahlen SE, Drazen JM, Evans JF, Serhan CN, et al. 2011. International Union of Basic and Clinical Pharmacology. LXXXIV: leukotriene receptor nomenclature, distribution, and pathophysiological functions. Pharmacol. Rev. 63:539-84
6. Banz WJ,Davis JE,Clough RW,Cheatwood JL. 2012. Stearidonic acid: Is there a role in the prevention and management of type 2 diabetes mellitus? J. Nutr. 142:635-40S
7. Bendsen NT, Christensen R, Bartels EM, Astrup A. 2011. Consumption of industrial and ruminant trans fatty acids and risk of coronary heart disease: a systematic review and meta-analysis of cohort studies. Eur. J. Clin. Nutr. 65:773-83
8. Briscoe CP, Peat AJ, McKeown SC, Corbett DF, Goetz AS, et al. 2006. Pharmacological regulation of insulin secretion in MIN6 cells through the fatty acid receptor GPR40: identification of agonist and antagonist small molecules. Br. J. Pharmacol. 148:619-28
9. Briscoe CP, TadayyonM, Andrews JL, BensonWG, Chambers JK, et al. 2003. The orphan G proteincoupled receptor GPR40 is activated by medium and long chain fatty acids. J. Biol. Chem. 278:11303-11
10. Brown AJ, Goldsworthy SM, Barnes AA, Eilert MM, Tcheang L, et al. 2003. The orphan G proteincoupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J. Biol. Chem. 278:11312-19
11. Burant CF, Viswanathan P, Marcinak J, Cao C, VakilynejadM, et al. 2012. TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 379:1403-11
12. Calder PC. 2007. Dietary arachidonic acid: harmful, harmless or helpful? Br. J. Nutr. 98:451-53
13. Calder PC. 2012. The role ofmarine omega-3 (n-3) fatty acids in inflammatory processes, atherosclerosis and plaque stability. Mol. Nutr. Food Res. 56:1073-80
14. Calder PC. 2014. Marine omega-3 fatty acids and inflammatory processes: effects, mechanisms and clinical relevance. Biochim. Biophys. Acta 1851:469-84
15. Cao H, Gerhold K, Mayers JR, Wiest MM, Watkins SM, Hotamisligil GS. 2008. Identification of a lipokine, a lipid hormone linking adipose tissue to systemic metabolism. Cell 134:933-44
16. Cartoni C, Yasumatsu K, Ohkuri T, Shigemura N, Yoshida R, et al. 2010. Taste preference for fatty acids is mediated by GPR40 and GPR120. J. Neurosci. 30:8376-82
17. Chao CY, Lii CK, Ye SY, Li CC, Lu CY, et al. 2014. Docosahexaenoic acid inhibits vascular endothelial growth factor (VEGF)-induced cell migration via the GPR120/PP2A/ERK1/2/eNOS signaling pathway in human umbilical vein endothelial cells. J. Agric. Food Chem. 62:4152-58
18. Christiansen E,Watterson KR, Stocker CJ, Sokol E, Jenkins L, et al. 2015. Activity of dietary fatty acids on FFA1 and FFA4 and characterization of pinolenic acid as a dual FFA1/FFA4 agonist with potential effect against metabolic diseases. Br. J. Nutr. doi: 10.1017/S000711451500118X
19. Cintra DE, Ropelle ER, Moraes JC, Pauli JR, Morari J, et al. 2012. Unsaturated fatty acids revert diet-induced hypothalamic inflammation in obesity. PLOS ONE 7:e30571
20. Conquer JA, Holub BJ. 1998. Effect of supplementation with different doses of DHA on the levels of circulating DHA as non-esterified fatty acid in subjects of Asian Indian background. J. Lipid Res. 39:286-92
21. Cornall LM, Mathai ML, Hryciw DH, McAinch AJ. 2011. Diet-induced obesity up-regulates the abundance of GPR43 and GPR120 in a tissue specific manner. Cell Physiol. Biochem. 28:949-58
22. Cornish J,MacGibbon A, Lin JM, Watson M, Callon KE, et al. 2008. Modulation of osteoclastogenesis by fatty acids. Endocrinology 149:5688-95
23. Davenport AP, Alexander SPH, Sharman JL, Pawson AJ, Benson HE, et al. 2013. International union of basic and clinical pharmacology. LXXXVIII. G protein-coupled receptor list: recommendations for new pairings with cognate ligands. Pharmacol. Rev. 65:967-86
24. Day JW, Ottaway N, Patterson JT, Gelfanov V, Smiley D, et al. 2009. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat. Chem. Biol. 5:749-57
25. Dilzer A, Park Y. 2012. Implication of conjugated linoleic acid (CLA) in human health. Crit. Rev. Food Sci. Nutr. 52:488-513
26. Donath MY, Shoelson SE. 2011. Type 2 diabetes as an inflammatory disease. Nat. Rev. Immunol. 11:98-107
27. Dranse HJ, Kelly MEM, Hudson BD. 2013. Drugs or diet? Developing novel therapeutic strategies targeting the free fatty acid family of GPCRs. Br. J. Pharmacol. 170:696-711
28. Edfalk S, Steneberg P, Edlund H. 2008. Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion. Diabetes 57:2280-87
29. Engelstoft MS, Park WM, Sakata I, Kristensen LV, Husted AS, et al. 2013. Seven transmembrane G protein-coupled receptor repertoire of gastric ghrelin cells. Mol. Metab. 2:376-92
30. Fodor JG, Helis E, Yazdekhasti N, Vohnout B. 2014. "Fishing" for the origins of the "Eskimos and heart disease" story: facts or wishful thinking? Can. J. Cardiol. 30:864-68
31. Folcik VA, Cathcart MK. 1994. Predominance of esterified hydroperoxy-linoleic acid in human monocyte-oxidized LDL. J. Lipid Res. 35:1570-82
32. Forbes JM, Cooper ME. 2013. Mechanisms of diabetic complications. Physiol. Rev. 93:137-88
33. Fredriksson R, Hoglund PJ, Gloriam DE, Lagerstrom MC, Schioth HB. 2003. Seven evolutionarily conserved human rhodopsinGprotein-coupled receptors lacking close relatives. FEBS Lett. 554:381-88
34. Galindo MM, Voigt N, Stein J, van Lengerich J, Raguse JD, et al. 2012. G protein-coupled receptors in human fat taste perception. Chem. Senses 37:123-39
35. GaultVA, Bhat VK, IrwinN, Flatt PR. 2013. A novel glucagon-like peptide-1 (GLP-1)/glucagon hybrid peptide with triple-acting agonist activity at glucose-dependent insulinotropic polypeptide,GLP-1, and glucagon receptors and therapeutic potential in high fat-fed mice. J. Biol. Chem. 288:35581-91
36. Gong Z, YoshimuraM, Aizawa S, Kurotani R, Zigman JM, et al. 2014. G protein-coupled receptor 120 signaling regulates ghrelin secretion in vivo and in vitro. Am. J. Physiol. Endocrinol. Metab. 306:E28-35
37. Gotoh C,Hong YH, Iga T,Hishikawa D, Suzuki Y, et al. 2007. The regulation of adipogenesis through GPR120. Biochem. Biophys. Res. Commun. 354:591-97
38. Gribble FM. 2012. The gut endocrine system as a coordinator of postprandial nutrient homoeostasis. Proc. Nutr. Soc. 71:456-62
39. Grosser T, Yu Y, Fitzgerald GA. 2010. Emotion recollected in tranquility: lessons learned from the COX-2 saga. Annu. Rev. Med. 61:17-33
40. Hansen HS, Rosenkilde MM, Holst JJ, Schwartz TW. 2012. GPR119 as a fat sensor. Trends Pharmacol. Sci. 33:374-81
41. HarrisWS, Miller M, Tighe AP, Davidson MH, Schaefer EJ. 2008. Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives. Atherosclerosis 197:12-24
42. Hauge M, Vestmar MA, Husted AS, Ekberg JP, Wright MJ, et al. 2015. GPR40 (FFAR1)-combined Gs and Gq signaling in vitro is associated with robust incretin secretagogue action ex vivo and in vivo. Mol. Metab. 4:3-14
43. Hirasawa A, TsumayaK, Awaji T, Katsuma S, AdachiT, et al. 2005. Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nat. Med. 11:90-94
44. Horrobin DF. 1992. Nutritional and medicinal importance of gamma-linolenic acid. Prog. Lipid Res. 31:163-94
45. Hotamisligil GS. 2006. Inflammation and metabolic disorders. Nature 444:860-67
46. Hudson BD, Shimpukade B,Mackenzie AE, Butcher AJ, Pediani JD, et al. 2013. The pharmacology of TUG-891, a potent and selective agonist of the free fatty acid receptor 4 (FFA4/GPR120), demonstrates both potential opportunity and possible challenges to therapeutic agonism. Mol. Pharmacol. 84:710-25
47. Hudson BD, Shimpukade B, Milligan G, Ulven T. 2014. The molecular basis of ligand interaction at free fatty acid receptor 4 (FFA4/GPR120). J. Biol. Chem. 289:20345-58
48. Ichimura A, Hirasawa A, Poulain-Godefroy O, Bonnefond A, Hara T, et al. 2012. Dysfunction of lipid sensor GPR120 leads to obesity in both mouse and human. Nature 483:350-54
49. Imig JD. 2012. Epoxides and soluble epoxide hydrolase in cardiovascular physiology. Physiol. Rev. 92:101-30
50. Itoh Y, Kawamata Y, Harada M, Kobayashi M, Fujii R, et al. 2003. Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. Nature 422:173-76
51. Johnson GH, Fritsche K. 2012. Effect of dietary linoleic acid on markers of inflammation in healthy persons: a systematic review of randomized controlled trials. J. Acad. Nutr. Diet. 112:1029-41.e15
52. Kallio H, Yang B, Peippo P, Tahvonen R, Pan R. 2002. Triacylglycerols, glycerophospholipids, tocopherols, and tocotrienols in berries and seeds of two subspecies (ssp. Sinensis and mongolica) of Sea Buckthorn (Hippophae rhamnoides). J. Agric. Food Chem. 50:3004-9
53. Karpe F, Dickmann JR, Frayn KN. 2011. Fatty acids, obesity, and insulin resistance: time for a reevaluation. Diabetes 60:2441-49
54. Katsuma S,Hatae N, Yano T, Ruike Y,KimuraM, et al. 2005. Free fatty acids inhibit serum deprivationinduced apoptosis through GPR120 in a murine enteroendocrine cell line STC-1. J. Biol. Chem. 280:19507-15
55. Kennedy A, Martinez K, Schmidt S,Mandrup S, LaPointK,McIntoshM. 2010. Antiobesity mechanisms of action of conjugated linoleic acid. J. Nutr. Biochem. 21:171-79
56. Kleinbongard P, Heusch G, Schulz R. 2010.TNFαin atherosclerosis, myocardial ischemia/reperfusion and heart failure. Pharmacol. Ther. 127:295-314
57. Koren N, Simsa-Maziel S, Shahar R, Schwartz B, Monsonego-Ornan E. 2014. Exposure to omega-3 fatty acids at early age accelerate bone growth and improve bone quality. J. Nutr. Biochem. 25:623-33
58. Korotkova M, Lundberg IE. 2014. The skeletal muscle arachidonic acid cascade in health and inflammatory disease. Nat. Rev. Rheumatol. 10:295-303
59. Kotarsky K, NilssonNE, Flodgren E, Owman C,Olde B. 2003. A human cell surface receptor activated by free fatty acids and thiazolidinedione drugs. Biochem. Biophys. Res. Commun. 301:406-10
60. Le Poul E, Loison C, Struyf S, Springael JY, Lannoy V, et al. 2003. Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation. J. Biol. Chem. 278:25481-89
61. Lehtonen HM, Jarvinen R, Linderborg K, Viitanen M, Venojarvi M, et al. 2010. Postprandial hyperglycemia and insulin response are affected by sea buckthorn (Hippophae rhamnoides ssp. Turkestanica) berry and its ethanol-soluble metabolites. Eur. J. Clin. Nutr. 64:1465-71
62. Lehtonen HM, Suomela JP, Tahvonen R, Yang B, VenojarviM, et al. 2011. Different berries and berry fractions have various but slightly positive effects on the associated variables of metabolic diseases on overweight and obese women. Eur. J. Clin. Nutr. 65:394-401
63. Li X, Yu Y, Funk CD. 2013. Cyclooxygenase-2 induction in macrophages is modulated by docosahexaenoic acid via interactions with free fatty acid receptor 4 (FFA4). FASEB J. 27:4987-97
64. Li Y, ZhangH, Jiang C, XuM, Pang Y, et al. 2013. Hyperhomocysteinemia promotes insulin resistance by inducing endoplasmic reticulum stress in adipose tissue. J. Biol. Chem. 288:9583-92
65. Liou AP, LuX, Sei Y, Zhao X, Pechhold S, et al. 2011. TheG-protein-coupled receptor GPR40 directly mediates long-chain fatty acid-induced secretion of cholecystokinin. Gastroenterology 140:903-12
66. LittleTJ, Isaacs NJ,YoungRL, OttR,NguyenNQ,et al. 2014. Characterization of duodenal expression and localization of fatty acid-sensing receptors in humans: relationships with body mass index. Am. J. Physiol. Gastrointest. Liver Physiol. 307:G958-67
67. LiuD,Wang L,MengQ, Kuang H, Liu X. 2012. G-protein coupled receptor 120 is involved in glucose metabolism in fat cells. Cell. Mol. Biol Suppl. 58:OL1757-62
68. Liu Y, Chen LY, Sokolowska M, Eberlein M, Alsaaty S, et al. 2014. The fish oil ingredient, docosahexaenoic acid, activates cytosolic phospholipase A2 via GPR120 receptor to produce prostaglandin E2 and plays an anti-inflammatory role in macrophages. Immunology 143:81-95
69. Lu X, Zhao X, Feng J, Liou AP, Anthony S, et al. 2012. Postprandial inhibition of gastric ghrelin secretion by long-chain fatty acid through GPR120 in isolated gastric ghrelin cells and mice. Am. J. Physiol. Gastrointest. Liver Physiol. 303:G367-76
70. Lumeng CN, Saltiel AR. 2011. Inflammatory links between obesity and metabolic disease. J. Clin. Invest. 121:2111-17
71. Luo J, Swaminath G, Brown SP, Zhang J, Guo Q, et al. 2012. A potent class of GPR40 full agonists engages the enteroinsular axis to promote glucose control in rodents. PLOS ONE 7:e46300
72. Luo P, Wang MH. 2011. Eicosanoids, β-cell function, and diabetes. Prostaglandins Other Lipid Mediat. 95:1-10
73. Ma J, Checklin HL,Wishart JM, Stevens JE, Jones KL, et al. 2013. A randomised trial of enteric-coated nutrient pellets to stimulate gastrointestinal peptide release and lower glycaemia in type 2 diabetes. Diabetologia 56:1236-42
74. Madsbad S, Dirksen C, Holst JJ. 2014. Mechanisms of changes in glucose metabolism and bodyweight after bariatric surgery. Lancet Diabetes Endocrinol. 2:152-64
75. Martin C, Chevrot M, Poirier H, Passilly-Degrace P, Niot I, Besnard P. 2011. CD36 as a lipid sensor. Physiol. Behav. 105:36-42
76. Martin C, Passilly-Degrace P, Chevrot M, Ancel D, Sparks SM, et al. 2012. Lipid-mediated release of GLP-1 by mouse taste buds from circumvallate papillae: putative involvement of GPR120 and impact on taste sensitivity. J. Lipid Res. 53:2256-65
77. Martinez JA, Navas-Carretero S, Saris WH, Astrup A. 2014. Personalized weight loss strategies\-The role of macronutrient distribution. Nat. Rev. Endocrinol. 10:749-60
78. Marzuillo P, Grandone A, Conte M, Capuano F, Cirillo G, et al. 2014. Novel association between a nonsynonymous variant (R270H) of the G-protein-coupled receptor 120 and liver injury in children and adolescents with obesity. J. Pediatr. Gastroenterol. Nutr. 59:472-75
79. Matsumura S, Eguchi A, MizushigeT,Kitabayashi N, Tsuzuki S, et al. 2009. Colocalization ofGPR120 with phospholipase-Cβ2 and α-gustducin in the taste bud cells in mice. Neurosci. Lett. 450:186-90
80. Micallef M, Munro I, Phang M, Garg M. 2009. Plasma n-3 polyunsaturated fatty acids are negatively associated with obesity. Br. J. Nutr. 102:1370-74
81. Micha R, Mozaffarian D. 2009. Trans fatty acids: effects on metabolic syndrome, heart disease and diabetes. Nat. Rev. Endocrinol. 5:335-44
82. Michalik L, Auwerx J, Berger JP, Chatterjee VK, Glass CK, et al. 2006. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol. Rev. 58:726-41
83. Milligan G, Ulven T, MurdochH,Hudson BD. 2014. G-protein-coupled receptors for free fatty acids: nutritional and therapeutic targets. Br. J. Nutr. 111:S3-7
84. Miyauchi S, Hirasawa A, Iga T, Liu N, Itsubo C, et al. 2009. Distribution and regulation of protein expression of the free fatty acid receptor GPR120. Naunyn-Schmiedeberg s Arch. Pharmacol. 379:427-34
85. Moore K, Zhang Q, Murgolo N, Hosted T, Duffy R. 2009. Cloning, expression, and pharmacological characterization of the GPR120 free fatty acid receptor from cynomolgus monkey: comparison with human GPR120 splice variants. Comp. Biochem. Physiol. B Biochem. Mol. Biol. 154:419-26
86. Morishita M, Tanaka T, Shida T, Takayama K. 2008. Usefulness of colon targeted DHA and EPA as novel diabetes medications that promote intrinsic GLP-1 secretion. J. Control. Release 132:99-104
87. Mu H, Porsgaard T. 2005. The metabolism of structured triacylglycerols. Prog. Lipid Res. 44:430-48
88. NilssonNE, Kotarsky K,OwmanC,OldeB. 2003. Identification of a free fatty acid receptor, FFA2R, expressed on leukocytes and activated by short-chain fatty acids. Biochem. Biophys. Res. Commun. 303:1047-52
89. Nobili V, Carpino G, Alisi A, De Vito R, Franchitto A, et al. 2014. Role of docosahexaenoic acid treatment in improving liver histology in pediatric nonalcoholic fatty liver disease. PLOS ONE 9:e88005
90. Nording ML, Yang J, Georgi K, Hegedus Karbowski C, German JB, et al. 2013. Individual variation in lipidomic profiles of healthy subjects in response to omega-3 fatty acids. PLOS ONE 8:e76575
91. Oh da Y, Walenta E, Akiyama TE, Lagakos WS, Lackey D, et al. 2014. A Gpr120-selective agonist improves insulin resistance and chronic inflammation in obese mice. Nat. Med. 20:942-47
92. Oh DY, Talukdar S, Bae EJ, Imamura T, Morinaga H, et al. 2010. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell 142:687-98
93. Olefsky JM, Glass CK. 2010. Macrophages, inflammation, and insulin resistance. Annu. Rev. Physiol. 72:219-46
94. OzdenerMH, Subramaniam S, Sundaresan S, Sery O, Hashimoto T, et al. 2014. CD36-and GPR120-mediated Ca2+ signaling in human taste bud cells mediates differential responses to fatty acids and is altered in obese mice. Gastroenterology 146:995-1005
95. Parker HE, Habib AM, Rogers GJ, Gribble FM, Reimann F. 2009. Nutrient-dependent secretion of glucose-dependent insulinotropic polypeptide from primary murine K cells. Diabetologia 52:289-98
96. PasmanWJ, Heimerikx J, Rubingh CM, van den Berg R, O Shea M, et al. 2008. The effect of Korean pine nut oil on in vitro CCK release, on appetite sensations and on gut hormones in post-menopausal overweight women. Lipids Health Dis. 7:10
97. Paulsen SJ, Larsen LK, Hansen G, Chelur S, Larsen PJ, Vrang N. 2014. Expression of the fatty acid receptor GPR120 in the gut of diet-induced-obese rats and its role in GLP-1 secretion. PLOS ONE 9:e88227
98. Pocai A, Carrington PE, Adams JR, Wright M, Eiermann G, et al. 2009. Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice. Diabetes 58:2258-66
99. Raptis DA, Limani P, Jang JH,UngethumU,Tschuor C, et al. 2014. GPR120 on Kupffer cells mediates hepatoprotective effects of ε3-fatty acids. J. Hepatol. 60:625-32
100. Rodriguez-Pacheco F, Garcia-Serrano S, Garcia-Escobar E, Gutierrez-Repiso C, Garcia-Arnes J, et al. 2014. Effects of obesity/fatty acids on the expression of GPR120. Mol. Nutr. Food Res. 58:1852-60
101. Rosell M, Kaforou M, Frontini A, Okolo A, Chan Y-W, et al. 2014. Brown and white adipose tissues: intrinsic differences in gene expression and response to cold exposure inmice. Am. J. Physiol. Endocrinol. Metab. 306:E945-64
102. Sadry SA, Drucker DJ. 2013. Emerging combinatorial hormone therapies for the treatment of obesity and T2DM. Nat. Rev. Endocrinol. 9:425-33
103. Scher JU, PillingerMH. 2009. The anti-inflammatory effects of prostaglandins. J. Invest.Med. 57:703-8
104. Schmidt J, Liebscher K, Merten N, Grundmann M, Mielenz M, et al. 2011. Conjugated linoleic acids mediate insulin release through islet G protein-coupled receptor FFA1/GPR40. J. Biol. Chem. 286:11890-94
105. Schuchardt JP, Hahn A. 2013. Bioavailability of long-chain omega-3 fatty acids. Prostaglandins Leukot. Essent. Fatty Acids 89:1-8
106. Scorletti E, Byrne CD. 2013. Omega-3 fatty acids, hepatic lipid metabolism, and nonalcoholic fatty liver disease. Annu. Rev. Nutr. 33:231-48
107. Serhan CN. 2014. Pro-resolving lipid mediators are leads for resolution physiology. Nature 510:92-101
108. Serhan CN, Petasis NA. 2011. Resolvins and protectins in inflammation resolution. Chem. Rev. 111:5922-43
109. Shimpukade B, Hudson BD, Hovgaard CK, Milligan G, Ulven T. 2012. Discovery of a potent and selective GPR120 agonist. J. Med. Chem. 55:4511-15
110. Sparks SM, Chen G, Collins JL, Danger D, Dock ST, et al. 2014. Identification of diarylsulfonamides as agonists of the free fatty acid receptor 4 (FFA4/GPR120). Bioorg. Med. Chem. Lett. 24:3100-3
111. Stoddart LA, Smith NJ,Milligan G. 2008. InternationalUnion of Pharmacology. LXXI. Free fatty acid receptors FFA1, -2, and -3: pharmacology and pathophysiological functions. Pharmacol. Rev. 60:405-17
112. Stone VM, Dhayal S, Brocklehurst KJ, Lenaghan C, Sorhede WinzellM, et al. 2014. GPR120 (FFAR4) is preferentially expressed in pancreatic delta cells and regulates somatostatin secretion from murine islets of Langerhans. Diabetologia 57:1182-91
113. Suckow AT, Polidori D, Yan W, Chon S, Ma JY, et al. 2014. Alteration of the glucagon axis in GPR120 (FFAR4) knockout mice: a role for GPR120 in glucagon secretion. J. Biol. Chem. 289:15751-63
114. Suzuki T, Igari SI, Hirasawa A, Hata M, Ishiguro M, et al. 2008. Identification of G protein-coupled receptor 120-selective agonists derived from PPARγagonists. J. Med. Chem. 51:7640-44
115. Sykaras AG, Demenis C, Case RM, McLaughlin JT, Smith CP. 2012. Duodenal enteroendocrine Icells contain mRNA transcripts encoding key endocannabinoid and fatty acid receptors. PLOS ONE 7:e42373
116. Talukdar S, Olefsky JM, Osborn O. 2011. Targeting GPR120 and other fatty acid-sensing GPCRs ameliorates insulin resistance and inflammatory diseases. Trends Pharmacol. Sci. 32:543-50
117. Tam CS, Berthoud HR, Bueter M, Chakravarthy MV, Geliebter A, et al. 2011. Could the mechanisms of bariatric surgery hold the key for novel therapies? Report from a Pennington Scientific Symposium. Obes. Rev. 12:984-94
118. Tanaka T, Katsuma S, Adachi T, Koshimizu TA, Hirasawa A, Tsujimoto G. 2008. Free fatty acids induce cholecystokinin secretion through GPR120. Naunyn Schmiedebergs Arch. Pharmacol. 377:523-27
119. Taneera J, Lang S, Sharma A, Fadista J, Zhou Y, et al. 2012. A systems genetics approach identifies genes and pathways for type 2 diabetes in human islets. Cell Metab. 16:122-34
120. Tomita T, Hosoda K, Fujikura J, Inagaki N, Nakao K. 2014. The G-protein-coupled long-chain fatty acid receptor GPR40 and glucose metabolism. Front. Endocrinol. 5:152
121. Turgeon SL, Rioux L-E. 2011. Food matrix impact on macronutrients nutritional properties. Food Hydrocolloids 25:1915-24
122. Ulven T. 2012. Short-chain free fatty acid receptors FFA2/GPR43 and FFA3/GPR41 as new potential therapeutic targets. Front. Endocrinol. 3:111
123. van der Wielen N, vanAvesaat M, de WitNJ, Vogels JT,Troost F, et al. 2014. Cross-species comparison of genes related to nutrient sensing mechanisms expressed along the intestine. PLOS ONE 9:e107531
124. Vannice G, RasmussenH. 2014. Position of the Academy ofNutrition and Dietetics: dietary fatty acids for healthy adults. J. Acad. Nutr. Diet. 114:136-53
125. Virtanen JK, Mursu J, Voutilainen S, Uusitupa M, Tuomainen TP. 2014. Serum omega-3 polyunsaturated fatty acids and risk of incident type 2 diabetes in men: the Kuopio Ischemic Heart Disease Risk Factor Study. Diabetes Care 37:189-96
126. Wagner R, Kaiser G, Gerst F, Christiansen E, Due-HansenME, et al. 2013. Reevaluation of fatty acid receptor 1 as a drug target for the stimulation of insulin secretion in humans. Diabetes 62:2106-11
127. Waguri T, Goda T, Kasezawa N, Yamakawa-Kobayashi K. 2013. The combined effects of genetic variations in the GPR120 gene and dietary fat intake on obesity risk. Biomed. Res. 34:69-74
128. Walker CG, Jebb SA, Calder PC. 2013. Stearidonic acid as a supplemental source of omega-3 polyunsaturated fatty acids to enhance status for improved human health. Nutrition 29:363-69
129. Wang JH, Wu XS, Simonavicius N, Tian H, Ling L. 2006. Medium-chain fatty acids as ligands for orphan G protein-coupled receptor GPR84. J. Biol. Chem. 281:34457-64
130. Watson SJ, Brown AJ, Holliday ND. 2012. Differential signaling by splice variants of the human free fatty acid receptor GPR120. Mol. Pharmacol. 81:631-42
131. Watterson KR, Hudson BD, Ulven T, Milligan G. 2014. Treatment of type 2 diabetes by free fatty acid receptor agonists. Front. Endocrinol. 5:137
132. Wellhauser L, Belsham DD. 2014. Activation of the omega-3 fatty acid receptor GPR120 mediates anti-inflammatory actions in immortalized hypothalamic neurons. J. Neuroinflammation 11:60
133. Widmayer P, Kuper M, Kramer M, Konigsrainer A, Breer H. 2012. Altered expression of gustatorysignaling elements in gastric tissue of morbidly obese patients. Int. J. Obes. 36:1353-59
134. Willett WC, StampferMJ. 2013. Current evidence on healthy eating. Annu. Rev. Public Health 34:77-95
135. Williams-Bey Y, Boularan C, Vural A,Huang NN, Hwang IY, et al. 2014. Omega-3 free fatty acids suppress macrophage inflammasome activation by inhibiting NF-κB activation and enhancing autophagy. PLOS ONE 9:e97957
136. WoodwardDF, Jones RL, Narumiya S. 2011. InternationalUnion of Basic and Clinical Pharmacology. LXXXIII: classification of prostanoid receptors, updating 15 years of progress. Pharmacol. Rev. 63:471-538
137. Wu JH, Micha R, Imamura F, Pan A, Biggs ML, et al. 2012. Omega-3 fatty acids and incident type 2 diabetes: a systematic review and meta-analysis. Br. J. Nutr. 107(Suppl. 2):S214-27
138. Xu H, Barnes GT, Yang Q, Tan G, Yang D, et al. 2003. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Invest. 112:1821-30
139. YanY, Jiang W, Spinetti T, Tardivel A, Castillo R, et al. 2013. Omega-3 fatty acids prevent inflammation and metabolic disorder through inhibition of NLRP3 inflammasome activation. Immunity 38:1154-63
140. Yanai H, Hamasaki H, Katsuyama H, Adachi H,Moriyama S, Sako A. 2015. Effects of intake of fish or fish oils on the development of diabetes. J. Clin. Med. Res. 7:8-12
141. Yin J, Zhang H, Ye J. 2008. Traditional Chinese medicine in treatment of metabolic syndrome. Endocr. Metab. Immune Disord. Drug Targets 8:99-111
142. Yore MM, Syed I, Moraes-Vieira PM, Zhang T, Herman MA, et al. 2014. Discovery of a class of endogenous mammalian lipids with anti-diabetic and anti-inflammatory effects. Cell 159:318-32
143. Zhang Y, Xu MT, Zhang SL, Yan L, Yang C, et al. 2007. The role of G protein-coupled receptor 40 in lipoapoptosis in mouse beta-cell line NIT-1. J. Mol. Endocrinol. 38:651-61